JPH0156050B2 - - Google Patents
Info
- Publication number
- JPH0156050B2 JPH0156050B2 JP61141773A JP14177386A JPH0156050B2 JP H0156050 B2 JPH0156050 B2 JP H0156050B2 JP 61141773 A JP61141773 A JP 61141773A JP 14177386 A JP14177386 A JP 14177386A JP H0156050 B2 JPH0156050 B2 JP H0156050B2
- Authority
- JP
- Japan
- Prior art keywords
- liver
- tablets
- results
- pronase
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 108010059712 Pronase Proteins 0.000 claims description 13
- 208000019423 liver disease Diseases 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 4
- 230000006806 disease prevention Effects 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 description 15
- 206010008909 Chronic Hepatitis Diseases 0.000 description 13
- 238000003745 diagnosis Methods 0.000 description 11
- 230000005856 abnormality Effects 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 239000003814 drug Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 208000019425 cirrhosis of liver Diseases 0.000 description 7
- 235000012054 meals Nutrition 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 206010016654 Fibrosis Diseases 0.000 description 4
- 108010067372 Pancreatic elastase Proteins 0.000 description 4
- 102000016387 Pancreatic elastase Human genes 0.000 description 4
- 229940000634 serratiopeptidase Drugs 0.000 description 4
- 108010038132 serratiopeptidase Proteins 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 101000856500 Bacillus subtilis subsp. natto Glutathione hydrolase proenzyme Proteins 0.000 description 3
- 108010004032 Bromelains Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 108010038346 Seaprose S Proteins 0.000 description 3
- 108010023197 Streptokinase Proteins 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 235000019835 bromelain Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229960005202 streptokinase Drugs 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000001883 cholelithiasis Diseases 0.000 description 2
- 239000007931 coated granule Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 208000001130 gallstones Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000007449 liver function test Methods 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229920001284 acidic polysaccharide Polymers 0.000 description 1
- 150000004805 acidic polysaccharides Chemical class 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 210000001953 common bile duct Anatomy 0.000 description 1
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960004533 streptodornase Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61141773A JPS61293927A (ja) | 1986-06-18 | 1986-06-18 | 肝臓疾患予防治療剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61141773A JPS61293927A (ja) | 1986-06-18 | 1986-06-18 | 肝臓疾患予防治療剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56125002A Division JPS5826822A (ja) | 1981-08-10 | 1981-08-10 | 慢性腎炎治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61293927A JPS61293927A (ja) | 1986-12-24 |
| JPH0156050B2 true JPH0156050B2 (OSRAM) | 1989-11-28 |
Family
ID=15299839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61141773A Granted JPS61293927A (ja) | 1986-06-18 | 1986-06-18 | 肝臓疾患予防治療剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS61293927A (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006130034A1 (fr) | 2005-04-25 | 2006-12-07 | Dmitry Dmitrievich Genkin | Procede pour prolonger la duree de vie d'animaux ou de l'humain |
| US8388951B2 (en) | 2003-07-14 | 2013-03-05 | Cls Therapeutics Limited | Method for treating systemic DNA mutation disease |
| US8710012B2 (en) | 2003-07-14 | 2014-04-29 | Cls Therapeutics Limited | Method for treating oncological diseases |
| US8431123B2 (en) | 2003-07-14 | 2013-04-30 | Cls Therapeutics Limited | Method for treating systemic bacterial, fungal and protozoan infection |
| EP1682168B1 (en) * | 2003-10-29 | 2013-05-01 | Eli Lilly And Co. | Non-pancreatic proteases for controlling plasma cholecystokinin (cck) concentration and for treating pain |
| US8871200B2 (en) | 2006-11-28 | 2014-10-28 | Cls Therapeutics Limited | Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method |
| US10617743B2 (en) | 2014-06-19 | 2020-04-14 | Cls Therapeutics Limited | Method to improve safety and efficacy of anti-cancer therapy |
| US11701410B2 (en) | 2015-05-22 | 2023-07-18 | Cls Therapeutics Limited | Extracellular DNA as a therapeutic target in neurodegeneration |
| JP2021510539A (ja) | 2018-01-16 | 2021-04-30 | シーエルエス セラピューティクス リミテッドＣＬＳ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | デオキシリボヌクレアーゼ（ＤＮａｓｅ）活性を有する酵素の肝臓発現による疾患の処置 |
-
1986
- 1986-06-18 JP JP61141773A patent/JPS61293927A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS61293927A (ja) | 1986-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0133085B2 (OSRAM) | ||
| JP3721196B2 (ja) | 新生物疾患および自己免疫疾患の治療または予防のためのマグネシウムベースの製品の使用 | |
| DiMagno | Gastric acid suppression and treatment of severe exocrine pancreatic insufficiency | |
| JPH0156050B2 (OSRAM) | ||
| JPS6314728A (ja) | 肝障害の予防、治療剤 | |
| WO2016101324A1 (zh) | 含有酶的天然组合物及其在制药中的应用 | |
| Adikwu et al. | Melatonin and alpha lipoic acid restore electrolytes and kidney morphology of lopinavir/ritonavir-treated rats | |
| WO1999022748A1 (en) | Remedies for ulcerative colitis | |
| JPH0213647B2 (OSRAM) | ||
| JP2003119148A (ja) | チアゾリジン誘導体の副作用軽減剤 | |
| Maruyama et al. | Chronic active hepatitis and liver cirrhosis in association with combined tamoxifen/tegafur adjuvant therapy | |
| JPS59225122A (ja) | 悪液質治療改善剤 | |
| CN114949122A (zh) | 一种治疗血瘀-阳亢-痰浊证高血压的中药组合物及其应用 | |
| CN105944078A (zh) | 一种用于治疗慢性肾盂肾炎的复方护理剂及其制备方法 | |
| JP2005524604A (ja) | 活性炭を含有する経口製剤及びその用途 | |
| JPS62215533A (ja) | 膠原病又は関節リウマチの予防治療剤 | |
| JPS608227A (ja) | 抗アレルギ−増強剤 | |
| ES2243068T3 (es) | Formulaciones farmaceuticas que comprenden beclometasona dipropionato para el tratamiento de la enfermedad intestinal inflamatoria. | |
| CN112656794B (zh) | 吡咯喹啉醌或其盐在制备用于防治前列腺增生药物中的用途及药物组合物 | |
| US20230193228A1 (en) | Lipase formulations and methods thereof | |
| JPH0351691B2 (OSRAM) | ||
| SU1284553A1 (ru) | Способ лечени хронического гломерулонефрита нефротического типа | |
| JPS58225026A (ja) | アミラ−ゼ活性および／またはリパ−ゼ活性亢進に起因する疾患の予防および治療剤 | |
| JP2025532357A (ja) | 肝機能障害の治療のためのニタゾキサニド | |
| Moshal | Nutrizym as a pancreatic enzyme replacement |